Zevra Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Neil McFarlane
Chief executive officer
US$3.4m
Total compensation
| CEO salary percentage | 4.6% |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety
Jun 28KemPharm exercises existing warrants and issues new ones in private placement
Jun 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$90m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
Compensation vs Market: Neil's total compensation ($USD3.45M) is above average for companies of similar size in the US market ($USD2.31M).
Compensation vs Earnings: Insufficient data to compare Neil's compensation with company performance.
CEO
Neil McFarlane (51 yo)
1.1yrs
Tenure
US$3,445,231
Compensation
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | no data | |
| Co-Founder & Chief Development Officer | no data | US$1.67m | 0.052% $ 239.1k | |
| CFO, Secretary & Treasurer | 9.4yrs | US$2.26m | 0.035% $ 162.2k | |
| Chief Commercial Officer & Executive VP of Business Development | 1.8yrs | US$1.82m | 0.0066% $ 30.7k | |
| Chief Scientific Officer | 1.8yrs | US$1.08m | 0.0052% $ 24.1k | |
| Vice President of Investor Relations & Corporate Communications | 2.3yrs | no data | no data | |
| Chief Legal Officer | less than a year | no data | no data | |
| Chief People Officer | less than a year | no data | no data | |
| Senior Vice President of Manufacturing | 1.8yrs | no data | no data | |
| Senior Vice President of Clinical Development | 1.8yrs | no data | no data | |
| Senior Vice President of Medical Affairs & Advocacy | 1.8yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
1.8yrs
Average Tenure
52yo
Average Age
Experienced Management: ZVRA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | no data | |
| Independent Director | 1.6yrs | US$274.00k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$258.02k | 0% $ 0 | |
| Independent Chair | 3.3yrs | US$324.39k | 0.0014% $ 6.3k | |
| Member of Scientific and Medical Advisory Board | no data | no data | no data | |
| Independent Director | 1.6yrs | US$264.31k | 0.057% $ 263.5k | |
| Independent Director | 1.6yrs | US$260.67k | 0.0029% $ 13.2k | |
| Chairman of Scientific and Medical Advisory Board | 17.8yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Co-Chair of Physician Advisory Council | 11.1yrs | no data | no data | |
| Co-Chair of Physician Advisory Council | 11.1yrs | no data | no data | |
| Independent Director | 1.3yrs | US$243.04k | 0.038% $ 175.7k |
1.6yrs
Average Tenure
58yo
Average Age
Experienced Board: ZVRA's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.